
## Anna J Waterreus

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3184671/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characteristics of people on community treatment orders in Australia: Data from the 2010 National Survey of High Impact Psychosis. Australian and New Zealand Journal of Psychiatry, 2022, 56, 788-799.	2.3	1
2	Health-related quality of life in people with psychotic disorders: The role of loneliness and its contributors. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1421-1433.	2.3	2
3	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
4	Health-Related Quality of Life, Functioning and Social Experiences in People with Psychotic Disorders. Applied Research in Quality of Life, 2021, 16, 1767-1783.	2.4	7
5	Mobilization after joint arthroplasty surgery: who benefits from standing within 12 hours?. ANZ Journal of Surgery, 2021, 91, 1271-1276.	0.7	2
6	Characteristics of people on long-acting injectable antipsychotics in Australia: Data from the 2010 National Survey of High Impact Psychosis. Australian and New Zealand Journal of Psychiatry, 2021, 55, 958-975.	2.3	4
7	Proposing a causal pathway for health-related quality of life in people with psychotic disorders. Journal of Psychiatric Research, 2021, 138, 550-559.	3.1	7
8	Loneliness, social isolation and suicide risk in people with psychotic disorders. Schizophrenia Research, 2021, 233, 60-61.	2.0	4
9	Validation of the Korean Version of the Psychosis Screener to Identify Patients With Psychosis. Psychiatry Investigation, 2021, 18, 736-742.	1.6	0
10	Mental health recovery and physical health outcomes in psychotic illness: Longitudinal data from the Western Australian survey of high impact psychosis catchments. Australian and New Zealand Journal of Psychiatry, 2020, 55, 000486742095426.	2.3	13
11	Loneliness and its association with health service utilization in people with a psychotic disorder. Schizophrenia Research, 2020, 223, 105-111.	2.0	14
12	Assessing physical activity in people with mental illness: 23-country reliability and validity of the simple physical activity questionnaire (SIMPAQ). BMC Psychiatry, 2020, 20, 108.	2.6	73
13	Changes over time in prevalence rates of past-year cannabis use by men and women with a psychotic disorder. Schizophrenia Research, 2020, 224, 198-200.	2.0	1
14	Loneliness in psychotic illness and its association with cardiometabolic disorders. Schizophrenia Research, 2019, 204, 90-95.	2.0	20
15	Sex differences in the cardiometabolic health of cannabis users with a psychotic illness. Drug and Alcohol Dependence, 2019, 194, 447-452.	3.2	6
16	Counting up the risks: How common are risk factors for morbidity and mortality in young people with psychosis?. Microbial Biotechnology, 2018, 12, 1045-1051.	1.7	7
17	Comorbid Diabetes and Depression in a National Sample of Adults With Psychosis. Schizophrenia Bulletin, 2018, 44, 84-92.	4.3	10
18	Treating body, treating mind: The experiences of people with psychotic disorders and their general practitioners – Findings from the Australian National Survey of High Impact Psychosis. Australian and New Zealand Journal of Psychiatry, 2018, 52, 561-572.	2.3	7

ANNA J WATERREUS

#	Article	IF	CITATIONS
19	Is cannabis a risk factor for suicide attempts in men and women with psychotic illness?. Psychopharmacology, 2018, 235, 2275-2285.	3.1	10
20	Responding to challenges for people with psychotic illness: Updated evidence from the Survey of High Impact Psychosis. Australian and New Zealand Journal of Psychiatry, 2017, 51, 124-140.	2.3	81
21	The impact of current cannabis use on general cognitive function in people with psychotic illness. Schizophrenia Research, 2017, 190, 164-171.	2.0	6
22	The role of arterial elasticity and cardiovascular peripheral resistance as clinically relevant indices of health status in people with psychosis. Schizophrenia Research, 2017, 184, 88-95.	2.0	2
23	The value of counting WHO-defined cardiovascular risk factors for death and disability in a national sample of adults with psychosis. Schizophrenia Research, 2017, 182, 13-18.	2.0	3
24	Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis. Epidemiology and Psychiatric Sciences, 2017, 26, 325-337.	3.9	23
25	Risk Factors for Obstructive Sleep Apnea Are Prevalent in People with Psychosis and Correlate with Impaired Social Functioning and Poor Physical Health. Frontiers in Psychiatry, 2016, 7, 139.	2.6	15
26	Correlates of physical activity in people living with psychotic illness. Acta Psychiatrica Scandinavica, 2016, 134, 129-137.	4.5	44
27	Metabolic syndrome in people with a psychotic illness: is cannabis protective?. Psychological Medicine, 2016, 46, 1651-1662.	4.5	20
28	Screening for the metabolic syndrome in Australia: a national survey of psychiatrists' attitudes and reported practice in patients prescribed antipsychotic drugs. Australasian Psychiatry, 2016, 24, 62-66.	0.7	13
29	Awareness of Pre-diabetes or Diabetes and Associated Factors in People With Psychosis. Schizophrenia Bulletin, 2016, 42, 1280-1289.	4.3	9
30	A multi-attribute utility instrument suitable for use in individuals with psychosis – the AQoL-4D: Findings from the Second Australian National Survey of Psychosis. European Psychiatry, 2016, 33, S82-S82.	0.2	0
31	Common familial risk factors for schizophrenia and diabetes mellitus. Australian and New Zealand Journal of Psychiatry, 2016, 50, 488-494.	2.3	21
32	Implementing evidence-based physical activity interventions for people with mental illness: an Australian perspective. Australasian Psychiatry, 2016, 24, 49-54.	0.7	61
33	Cardiovascular risk factor associations in adults with psychosis and adults in a national comparator sample. Australian and New Zealand Journal of Psychiatry, 2015, 49, 714-723.	2.3	11
34	Effect of age, family history of diabetes, and antipsychotic drug treatment on risk of diabetes in people with psychosis: a population-based cross-sectional study. Lancet Psychiatry,the, 2015, 2, 1092-1098.	7.4	22
35	Inadequate fruit and vegetable intake in people with psychosis. Australian and New Zealand Journal of Psychiatry, 2014, 48, 1025-1035.	2.3	40
36	Psychosis prevalence and physical, metabolic and cognitive co-morbidity: data from the second Australian national survey of psychosis. Psychological Medicine, 2014, 44, 2163-2176.	4.5	155

ANNA J WATERREUS

#	Article	IF	CITATIONS
37	Cardiometabolic Risk Indicators That Distinguish Adults with Psychosis from the General Population, by Age and Gender. PLoS ONE, 2013, 8, e82606.	2.5	41
38	Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 2012, 46, 753-761.	2.3	166
39	Medication for psychosis – consumption and consequences: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 2012, 46, 762-773.	2.3	51
40	People living with psychotic illness in 2010: The second Australian national survey of psychosis. Australian and New Zealand Journal of Psychiatry, 2012, 46, 735-752.	2.3	405
41	Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm. Medical Journal of Australia, 2009, 190, 185-189.	1.7	44
42	Two-Year Outcomes From a Cessation of Smoking Intervention in Older Adults. Journal of Smoking Cessation, 2008, 3, 101-109.	1.0	7
43	The diagnostic interview for psychoses (DIP): development, reliability and applications. Psychological Medicine, 2006, 36, 69-80.	4.5	314
44	Effect of testosterone deprivation on the cognitive performance of a patient with Alzheimer's disease. International Journal of Geriatric Psychiatry, 2001, 16, 823-825.	2.7	11